AR045362A1 - Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona - Google Patents

Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona

Info

Publication number
AR045362A1
AR045362A1 ARP040102906A ARP040102906A AR045362A1 AR 045362 A1 AR045362 A1 AR 045362A1 AR P040102906 A ARP040102906 A AR P040102906A AR P040102906 A ARP040102906 A AR P040102906A AR 045362 A1 AR045362 A1 AR 045362A1
Authority
AR
Argentina
Prior art keywords
monometansulfonate
benzoxazolona
bifenil
ilmetil
piperazinil
Prior art date
Application number
ARP040102906A
Other languages
English (en)
Inventor
Gerrit Klein
Amstel Maria J L Terhorst-Van
Klaas Zwier
Irene Eijgendaal
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR045362A1 publication Critical patent/AR045362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a una forma polimórfica estable del compuesto monometansulfonarto de 7-[4-([1,1´-bifenil]-3-ilmetil)-1-piperazinil]-2(3H)-benzoxazolona (INNM mesilato de bifeprunox), un método para la preparación de dicha forma polimórfica y su uso en productos farmacéuticos, especialmente en productos farmacéuticos para el tratamiento de desórdenes psicóticos y enfermedad de Parkinson. Reivindicación 1: Un polimorfo cristalino de monometansulfonato de 7-[4-([1,1´-bifenil]-3-ilmetil)-1-piperazinil]-2(3H)-benzoxazolona, que exhibe un diagrama de difracción en polvo de rayos X que tiene los picos característicos expresados en grados 2q a aproximadamente 7,0, 9,3, 10,0, 12,5, 15,4, 16,7, 17,2, 17,4, 17,7, 18,7, 21,3, 22,2, 25,2, 27,2, 28,3, 28,8 y 30,1.
ARP040102906A 2003-08-18 2004-08-13 Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona AR045362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03102573 2003-08-18

Publications (1)

Publication Number Publication Date
AR045362A1 true AR045362A1 (es) 2005-10-26

Family

ID=34924088

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102906A AR045362A1 (es) 2003-08-18 2004-08-13 Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona

Country Status (26)

Country Link
EP (1) EP1656358B1 (es)
JP (1) JP2007502802A (es)
CN (1) CN100422159C (es)
AR (1) AR045362A1 (es)
AT (1) ATE499348T1 (es)
AU (1) AU2004265104B2 (es)
BR (1) BRPI0413617A (es)
CA (1) CA2536149C (es)
DE (1) DE602004031534D1 (es)
DK (1) DK1656358T3 (es)
EA (1) EA008182B1 (es)
ES (1) ES2361508T3 (es)
IS (1) IS8279A (es)
ME (1) MEP37108A (es)
MX (1) MXPA06001881A (es)
MY (1) MY139462A (es)
NO (1) NO20061265L (es)
NZ (1) NZ545415A (es)
PL (1) PL1656358T3 (es)
PT (1) PT1656358E (es)
RS (1) RS20060113A (es)
SI (1) SI1656358T1 (es)
TW (1) TWI336695B (es)
UA (1) UA85562C2 (es)
WO (1) WO2005016898A2 (es)
ZA (1) ZA200601399B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
AU2007291234A1 (en) 2006-08-31 2008-03-06 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9675101B2 (en) 2013-03-15 2017-06-13 Whirlpool Corporation High performance adjustable juicer with whole foods feed chute

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2271967T3 (es) * 1996-03-29 2007-04-16 Duphar International Research B.V Compuestos de piperazina y piperidina.
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO1999032115A1 (en) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos

Also Published As

Publication number Publication date
PT1656358E (pt) 2011-05-12
ES2361508T3 (es) 2011-06-17
TWI336695B (en) 2011-02-01
DK1656358T3 (da) 2011-05-30
MXPA06001881A (es) 2006-05-17
AU2004265104B2 (en) 2009-06-04
DE602004031534D1 (de) 2011-04-07
JP2007502802A (ja) 2007-02-15
PL1656358T3 (pl) 2011-07-29
EA008182B1 (ru) 2007-04-27
ATE499348T1 (de) 2011-03-15
CA2536149C (en) 2011-03-22
MEP37108A (en) 2011-02-10
WO2005016898A3 (en) 2005-04-07
SI1656358T1 (sl) 2011-06-30
BRPI0413617A (pt) 2006-10-17
EA200600442A1 (ru) 2006-08-25
CN1835935A (zh) 2006-09-20
WO2005016898B1 (en) 2005-05-19
NZ545415A (en) 2009-11-27
IS8279A (is) 2006-01-31
UA85562C2 (en) 2009-02-10
AU2004265104A1 (en) 2005-02-24
RS20060113A (sr) 2008-09-29
EP1656358A2 (en) 2006-05-17
ZA200601399B (en) 2007-04-25
EP1656358B1 (en) 2011-02-23
MY139462A (en) 2009-10-30
TW200513462A (en) 2005-04-16
NO20061265L (no) 2006-05-09
WO2005016898A2 (en) 2005-02-24
CA2536149A1 (en) 2005-02-24
CN100422159C (zh) 2008-10-01

Similar Documents

Publication Publication Date Title
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
MY138352A (en) Benzothiazole derivatives
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
AR087208A2 (es) FORMA CRISTALINA DE 1-CLORO-4-(b-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO, UN METODO PARA SU PREPARACION Y EL USO DEL MISMO PARA PREPARAR MEDICAMENTOS
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
TW200621762A (en) Novel compounds
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
SG170785A1 (en) Benzothiazoles having histamine h3 receptor activity
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
CL2007002897A1 (es) Uso de un antagonista (sartan) del receptor 1 (at-1) de angiotensina ii para la preparacion de una composicion farmaceutica para el tratamiento de una enfermedad generalizada en gatos; metodo para la profilaxis o el tratamiento de una enfermedad en g
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
CL2008002808A1 (es) Compuestos derivados de benzoxazol, agonistas del receptor muscarinico m1; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamiento de esquizofrenia, alteraciones cognitivas o enfermedad de alzheimer.
JP2008513510A5 (es)
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR045362A1 (es) Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
TW200735878A (en) Pharmaceutical compositions
CR10210A (es) Derivados de benzoisoindol para el tratamiento del dolor
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
BRPI0413500A (pt) compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
FR2842525B1 (fr) Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant

Legal Events

Date Code Title Description
FB Suspension of granting procedure